Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Melanoma sample provides bit of an answer

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Apr 20, 2023 4:27pm

54 Views

Post# 35406082

RE:Melanoma sample provides bit of an answer

That's brilliant thanks.

Wino115 wrote: Looks like the reason the graphs don't go much beyond 20 days is that the sample everyone uses to test an immunogenic tumor in mice is one that rapidly grows (doubles every 2-3 days), is suggested to test with only 2 doses, and typically leads to euthanasia criteria within 20-25 days for the mice.

This was a link from the Jones report that talks about it with various charts showing PD-1 and PD-L1 and other chemos all seeing that huge jump in 10 -14 days. I suppose you can look at it as a test of a super-aggressive tumor cell line that does in 20 days with mice what it would do in a longer period in humans. But it only lends itself to a 2 dose schedule and a 20-25 day total trial period according to the manufacture.

https://drugdevelopment.labcorp.com/industry-solutions/oncology/preclinical/tumor-spotlights/b16-f10-a-murine-melanoma-model.html

"Our growth studies show efficient growth kinetics following a range of inocula with a doubling time of approximately 2-3 days (Fig. 1). Control animals stay on study for 20-25 days before they reach euthanasia criteria of excessive tumor burden. This results in a model which can facilitate up to a two-week dosing window for test agents to elicit their anti-tumor activity."